Alnylam initiated with a Buy at Canaccord

Canaccord analyst Whitney Ijem initiated coverage of Alnylam with a Buy rating and $310 price target. Having pioneered the technology that potently and specifically silences the expression of disease-causing genes, Ijem calls Alnylam "the RNAi company." While there is a lot of investor focus on the near-term regulatory decision for Onpattro in ATTR-cardiomyopathy, or ATTR-CM, Ijem thinks to over-focus on Onpattro in the near term is to "miss the forest for the trees," with the forest being the "massive opportunity in ATTR."